Skip to main content

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension

Heart and Vessels volume 25, pages 144–149 (2010)Cite this article

Abstract

We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models. In the present study, we examined acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, as a more feasible option to locally deliver the drug for PAH. We examined 15 patients with PAH (13 women and 2 men, 45 ± 4 years old), including idiopathic PAH (n = 5), PAH associated with connective tissue disease (n = 6), PAH with congenital heart disease (n = 3), and portal PAH (n = 1). In those patients, we performed right heart catheterization with a Swan-Ganz catheter in the two protocols with inhalation of nitric oxide (NO) (40 ppm, 10 min) and fasudil (30 mg, 10 min) with a sufficient interval (>30 min). Both NO and fasudil inhalation significantly reduced mean pulmonary arterial pressure (PAP) (NO: P < 0.01, fasudil: P < 0.05) and tended to decrease pulmonary vascular resistance (NO: P = 0.07, fasudil: P = 0.1), but did not affect cardiac index. The ratio of pulmonary to systemic vascular resistance was significantly reduced both in NO and fasudil inhalation (NO: P < 0.01, fasudil: P < 0.05), indicating that both NO and fasudil inhalation selectively affect lung tissues. Interestingly, there was no correlation in the vasodilator effects between NO and fasudil, and a positive correlation with serum levels of high-sensitivity C-reactive protein was noted for fasudil but not for NO. These results suggest that inhalation of fasudil is as effective as NO in patients with PAH, possibly through different mechanisms.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43:40S–47S

    Article  PubMed  Google Scholar 

  2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S–24S

    Article  CAS  PubMed  Google Scholar 

  3. McLaughlin VV, McGoon MD (2006) Pulmonary arterial hypertension. Circulation 114:1417–1431

    Article  PubMed  Google Scholar 

  4. Fukumoto Y, Tawara S, Shimokawa H (2007) Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Tohoku J Exp Med 211:309–320

    Article  CAS  PubMed  Google Scholar 

  5. Shimokawa H (2000) Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J 64:1–12

    Article  CAS  PubMed  Google Scholar 

  6. Shimokawa H, Takeshita A (2005) Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25:1767–1775

    Article  CAS  PubMed  Google Scholar 

  7. Shimokawa H (2002) Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39:319–327

    Article  CAS  PubMed  Google Scholar 

  8. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A (2004) Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94:385–393

    Article  CAS  PubMed  Google Scholar 

  9. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF (2004) Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 287: L656–L664

    Article  CAS  PubMed  Google Scholar 

  10. Nagaoka T, Fagan KA, Gebb SA, Morris KG, Suzuki T, Shimokawa H, McMurtry IF, Oka M (2005) Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171:494–499

    Article  PubMed  Google Scholar 

  11. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H (2005) Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91:391–392

    Article  CAS  PubMed  Google Scholar 

  12. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H (2006) Long-term inhibition of Rhokinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 48:280–285

    Article  CAS  PubMed  Google Scholar 

  13. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, Nakano T (2006) Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 70:174–178

    Article  CAS  PubMed  Google Scholar 

  14. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF (2007) Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100:923–929

    Article  CAS  PubMed  Google Scholar 

  15. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S (1997) Calcium sensitization of smooth muscle mediated by a Rhoassociated protein kinase in hypertension. Nature 389:990–994

    Article  CAS  PubMed  Google Scholar 

  16. Somlyo AP, Somlyo AV (2000) Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and nonmuscle myosin II. J Physiol 522Pt 2:177–185

    Article  CAS  PubMed  Google Scholar 

  17. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A (2002) Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545–1547

    Article  CAS  PubMed  Google Scholar 

  18. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A (2003) Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 41:15–19

    Article  CAS  PubMed  Google Scholar 

  19. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275–285

    CAS  PubMed  Google Scholar 

  20. Dorfmuller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358–363

    Article  CAS  PubMed  Google Scholar 

  21. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A (2004) Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 37: 537–546

    Article  CAS  PubMed  Google Scholar 

  22. Liao JK, Seto M, Noma K (2007) Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 50:17–24

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan

    Hiroshi Fujita, Yoshihiro Fukumoto, Kenya Saji, Koichiro Sugimura, Jun Demachi, Jun Nawata & Hiroaki Shimokawa

Authors
  1. Hiroshi Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshihiro Fukumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenya Saji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koichiro Sugimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Demachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Nawata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroaki Shimokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshihiro Fukumoto.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fujita, H., Fukumoto, Y., Saji, K. et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25, 144–149 (2010). https://doi.org/10.1007/s00380-009-1176-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-009-1176-8

Key words

  • Rho-kinase
  • Inhalation
  • Pulmonary arterial hypertension
  • Pulmonary arterial pressure
  • Pulmonary vascular resistance